ArticleBMC nephrology2026
L-Carnitine, a new biomarker screened based on untargeted metabolomics, predict cardiac surgery-associated acute kidney injury: a prospective cohort study.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Low-dose l-carnitine supplementation attenuates hepatic lipid accumulation in chow-fed mice: Insights from integrated multi-omics analysis.Food chemistry. Molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to evaluate the diagnostic potential of L-carnitine (LC) for the early detection of cardiac surgery-associated acute kidney injury (CSA-AKI).
methodsWe collected clinical data and serum samples from 27 patients admitted to the Intensive Care Unit (ICU) of Nanjing Medical University Affiliated Nanjing Hospital between February 2024 and March 2024. Among these, 13 patients were diagnosed with CSA-AKI, while 14 served as non-AKI controls. Untargeted metabolomic analysis revealed LC as a differentially expressed metabolite between the two groups. In addition, clinical data and serum samples were prospectively collected from patients undergoing cardiac surgery at Nanjing Medical University Affiliated Nanjing Hospital between May 2024 and July 2024. Serum samples were taken preoperatively (immediately upon entering the operating room) and postoperatively (immediately upon ICU admission). The levels of blood urea nitrogen (BUN), serum creatinine (Scr), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and LC were measured. Multivariate logistic regression analysis was used to find independent risk variables for CSA-AKI. The predictive performance of the biomarkers, the clinical model, and their combination were evaluated using the area under the receiver operating characteristic curve (AUC).
resultsThis study included 170 patients who met the inclusion criteria for cardiac surgery. The incidence of CSA-AKI was 27.06% (46/170). Multivariate logistic regression analysis indicated that preoperative heart failure, vasopressor-inotropic score, and postoperative partial pressure of oxygen were independent risk factors for the development of CSA-AKI. Serum biomarker analysis showed significant differences in BUN, Scr, NGAL, and LC levels before and after cardiac surgery. After surgery, LC levels in patients with CSA-AKI were considerably lower than those in patients without CSA-AKI. Postoperative LC showed significant predictive value for CSA-AKI, with an AUC of 0.777 (95%CI: 0.697–0.857, P < 0.001). Incorporating postoperative LC into the clinical model significantly enhanced its predictive performance.
conclusionPostoperative LC can effectively predict the occurrence of CSA-AKI, and when integrated into a clinical prediction model, it enhances the model’s predictive performance for CSA-AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.